Key Segments:
By Product Type
-
Technetium-99m Generators
-
Radiopharmaceutical Kits
-
Ready-to-Use Radiopharmaceuticals
-
Cyclotron-Produced Tc-99m
By Modality
-
Gamma Camera
-
SPECT
By Clinical Service
-
Cardiac Scans
-
Bone Scans
-
Renal Scans
-
Neurology Scans
-
Pulmonary Scans
-
Thyroid Scans
-
Oncology Scans
-
Others
By End User
-
Hospitals
-
Diagnostic Imaging Centers
-
Nuclear Medicine Centers
-
Ambulatory Surgical Centers
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market includes Curium Pharma, GE HealthCare, Jubilant Pharmova, NTP Radioisotopes, Bracco Imaging, Institute of Isotopes, ANSTO, NCBJ POLATOM, ARTMS, China Isotope & Radiation Corporation, Eczacibasi-Monrol, Eckert & Ziegler, Isotopia Molecular Imaging, Medi-Radiopharma, Rotop Pharmaka, NRG PALLAS, and the Institute for Radioelements, among others.
The main opportunities lie in regulatory approval of non-reactor and power-reactor-based production routes, international supply partnerships, government financing for new production facilities, and replacement-cycle demand for higher-sensitivity SPECT/CT systems.
The key growth factor is rising cardiovascular, oncologic and neurodegenerative disease burden in an aging population, combined with expanding regulatory clearance of improved SPECT and SPECT/CT hardware.
By product type, the Technetium-99m Generators segment dominated the market with approximately 48.50% share in 2025, supported by decades of regulatory-approved hospital nuclear pharmacy use.
North America dominated the market with approximately 37.70% share in 2025, supported by its established nuclear pharmacy network. Asia Pacific is the fastest-growing region with a projected CAGR of approximately 7.40% from 2026 to 2035.
